Becquemin J P, Aksoy M, Marzelle J, Roudot-Thoraval F, Desgranges P, Allaire E, Kobeiter H
Department of Vascular Surgery, Henri Mondor Hospital, University Paris XII, Creteil, France.
J Cardiovasc Surg (Torino). 2008 Apr;49(2):199-206.
Aneurysm shrinkage is an expected outcome after stent-grafting for abdominal aortic aneurysm (AAA). A worrying problem following repair is progressive enlargement indicating persistent sac pressurization: in this setting not all grafts are equal. The Cook Zenith device (CZ) became available on the European market in 1999. While multicenter studies on the device have shown favorable clinical results at mid-term follow-up, few have focused on sac behavior. This study evaluated AAA sac behavior and predictive factors of its evolution by assessing the five-year results obtained with the CZ graft in a single-institution experience.
All consecutive elective surgery patients treated with a CZ graft for infrarenal aortic or aortoiliac aneurysm repair from January 2000 to November 2004 in our institution were included prospectively in the study and followed at 1, 6, 12, 18, 24 months and yearly thereafter. Pre-, intra- and postoperative data were recorded in a computerized database. Computed tomography (CT) scans were reviewed by a senior radiologist to identify any abnormalities including endoleak and graft malfunction. Pre- and postoperative maximum sac diameters were derived from measurements of CT findings and then compared. A change of at least 8 mm in sac size was considered significant. Overall results are expressed according to the Committee on Reporting Standards of AAA treatment. Factors that may have influenced sac behavior were analyzed by dividing the patients into 3 groups according to whether the sac diameter remained unchanged (group 1), had increased (group 2) or regressed (group 3). Statistical analysis of the demographic and CT-scan data was then performed.
The study sample was 212 consecutive patients (mean age 72.8+/-9.0 years); the mean aneurysm diameter before treatment was 55.5+/-9.8 mm. All stent grafts were successfully implanted. The 30-day mortality rate was 0.94% (2/212); the morbidity rate was 11.7% (25/212). The primary technical success rate was 93.40%; the assisted primary technical success and secondary technical success rates were 96.63% and 99.52%, respectively. The mean follow-up period was 17.7+/-14.7 (1-60) months. The cumulative survival probability was 94%, 84.2%, and 72.9% at 12, 24, and 36 months, respectively. The endoleak-free survival probabilities at 12 and 24 months were 75.7% and 62.8%, respectively. The free of intervention survival rates were 82.1%, 68.9% and 60.6% at 12, 24 and 38 months, respectively. At five years follow-up, the overall clinical success rate was 49.5%. If changes in sac diameter occurred, they were noted at 13 months on average. Sac size remained unchanged in 115 (54.3%) patients (group 1), increased in 9 (4.2%) (group 2), and regressed in 88 (41.5%) (group 3). Neither preoperative patient demographics nor aneurysm characteristics were found to be predictive of sac behavior. Aortouniliac graft configuration was predictive of sac shrinkage (P=0.020). Endoleak was more frequent among patients in groups 1 (27/115; 23%) and 2 (5/9; 56%) than among those in group 3 (9/88;10%) (P=0.001). Reduction in aneurysm sac diameter was less marked in patients with any type of endoleak (P=0.0003).
The CZ grafts offered satisfactory overall results up to five years of follow-up; nevertheless, sac diameter increased in 4.25% of patients. Endoleak was a predictive factor of a lack of sac shrinkage, while aortouniliac graft configuration was predictive of sac shrinkage.
腹主动脉瘤(AAA)腔内修复术后瘤体缩小是预期的结果。修复术后一个令人担忧的问题是瘤体持续增大,提示瘤腔内仍有压力:在这种情况下,并非所有的移植物效果都相同。Cook Zenith装置(CZ)于1999年进入欧洲市场。虽然关于该装置的多中心研究在中期随访时显示了良好的临床效果,但很少有研究关注瘤腔的变化情况。本研究通过评估单中心使用CZ移植物获得的五年结果,来评价AAA瘤腔变化情况及其演变的预测因素。
2000年1月至2004年11月期间,在本机构接受CZ移植物治疗肾下腹主动脉瘤或主-髂动脉瘤的所有连续择期手术患者均被前瞻性纳入本研究,并在术后1、6、12、18、24个月及之后每年进行随访。术前、术中和术后数据均记录在计算机数据库中。由一位资深放射科医生复查计算机断层扫描(CT)图像,以识别任何异常情况,包括内漏和移植物故障。术前和术后瘤腔最大直径通过测量CT结果得出,然后进行比较。瘤腔大小至少改变8mm被认为有显著意义。总体结果根据AAA治疗报告标准委员会的标准进行表述。根据瘤腔直径是否保持不变(第1组)、增大(第2组)或缩小(第3组),将患者分为3组,分析可能影响瘤腔变化的因素。然后对人口统计学和CT扫描数据进行统计分析。
研究样本为212例连续患者(平均年龄72.8±9.0岁);治疗前动脉瘤平均直径为55.5±9.8mm。所有支架型人工血管均成功植入。30天死亡率为0.94%(2/212);发病率为11.7%(25/212)。主要技术成功率为93.40%;辅助主要技术成功率和次要技术成功率分别为96.63%和99.52%。平均随访期为17.7±14.7(1 - 60)个月。12、24和36个月时的累积生存概率分别为94%、84.2%和72.9%。12个月和24个月时无内漏生存概率分别为75.7%和62.8%。12、24和38个月时无需干预生存率分别为82.1%、68.9%和60.6%。在五年随访时,总体临床成功率为49.5%。如果瘤腔直径发生变化,平均在13个月时被发现。115例(54.3%)患者瘤腔大小保持不变(第1组),9例(4.2%)增大(第2组),88例(41.5%)缩小(第3组)。术前患者人口统计学特征和动脉瘤特征均未发现可预测瘤腔变化情况。主-髂移植物构型可预测瘤腔缩小(P = 0.020)。第1组(27/115;23%)和第2组(5/9;56%)患者的内漏发生率高于第3组(9/88;10%)(P = 0.001)。任何类型内漏的患者,动脉瘤瘤腔直径缩小均不明显(P = 0.0003)。
CZ移植物在长达五年的随访中总体结果令人满意;然而,4.25%的患者瘤腔直径增大。内漏是瘤腔缺乏缩小的预测因素,而主-髂移植物构型是瘤腔缩小的预测因素。